Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services announced a strategic collaboration under which Piramal will refer applicable customers seeking ADC manufacturing technology to Aji Bio-Pharma and AJICAP™. Aji Bio-Pharma will refer Piramal to customers as a potential CDMO for manufacturing products using AJICAP™ technology, supporting their programs across development and manufacturing.
Following the execution of this agreement, Piramal and Ajinomoto will enter into a separate Material Transfer Agreement (MTA) to allow the transfer of technology between companies. The MTA will equip Piramal with the expertise, capabilities, and personnel for it to manufacture AJICAP™-based products with precision and speed.
As the world’s first FDA-approved ADC CDMO, Piramal brings over two decades of experience to the field. The Company also pioneered commercial ADC manufacturing, earning it more than 15 years of specialized expertise. With a global network of state-of-the-art facilities, Piramal has developed hundreds of ADCs, completed thousands of batches, and currently manufactures multiple commercial ADCs. Ongoing expansions are increasing Piramal’s commercial-scale ADC capacity.
Ajinomoto’s AJICAP™ technology facilitates the development of site-specific ADCs and linker technologies through simple, efficient processes, empowering early-stage pharmaceutical developers to create ADCs with higher efficacy and lower toxicity. Pairing this innovative platform with Piramal’s clinical and commercial ADC GMP manufacturing expertise enables customers to accelerate development, streamline tech transfer, and simplify scale-up.
“We are excited to collaborate with Ajinomoto Bio-Pharma Services and enhance our ADC platform by offering manufacturing support for AJICAP™-based products,” said Peter DeYoung, CEO, Piramal Global Pharma. “With the implementation of these capabilities, we will accelerate innovation and expand access to this technology for our customers and their patients worldwide.”
“This collaboration with Piramal expands the ecosystem supporting AJICAP™ technology by connecting licensed customers with an experienced ADC manufacturing partner,” said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. “Through this collaboration, we aim to provide our customers with streamlined pathways and access to deep ADC expertise to advance high-quality programs from early development through commercial manufacturing.”
By combining AJICAP™’s site-specific conjugation technology with Piramal’s extensive development and manufacturing expertise, this collaboration will help customers deliver safe, effective, and precise ADC therapies with exceptional efficiency.